Improving access to haemophilia therapies—Beyond humanitarian aid

Farrugia, Albert; Liumbruno, Giancarlo Maria; Calizzani, Gabriele; Candura, Fabio; Profili, Samantha; Cassar, Josephine

doi:10.1111/hae.13619

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pasteurization, terminal dry heat, and vapor heat treatment represent complementary techniques to inactivate lipid-enveloped and selective nonlipid-enveloped pathogens. 21 22 23…”

Section: Plasma-derived Factor VIII Replacement Therapymentioning

confidence: 99%

Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment

Chandran,

Tohit,

Stanslas

et al. 2024

Semin Thromb Hemost

View full text Add to dashboard Cite

The management of hemophilia A has undergone a remarkable revolution, in line with technological advancement. In the recent past, the primary concern associated with Factor VIII (FVIII) concentrates was the risk of infections, which is now almost resolved by advanced blood screening and viral inactivation methods. Improving patients' compliance with prophylaxis has become a key focus, as it can lead to improved health outcomes and reduced health care costs in the long term. Recent bioengineering research is directed toward prolonging the recombinant FVIII (rFVIII) coagulant activity and synthesising higher FVIII yields. As an outcome, B-domain deleted, polyethylene glycolated, single-chain, Fc-fused rFVIII, and rFVIIIFc-von Willebrand Factor-XTEN are available for patients. Moreover, emicizumab, a bispecific antibody, is commercially available, whereas fitusiran and tissue factor pathway inhibitor are in clinical trial stages as alternative strategies for patients with inhibitors. With these advancements, noninfectious complications, such as inhibitor development, allergic reactions, and thrombosis, are emerging concerns requiring careful management. In addition, the recent approval of gene therapy is a major milestone toward a permanent cure for hemophilia A. The vast array of treatment options at our disposal today empowers patients and providers alike, to tailor therapeutic regimens to the unique needs of each individual. Despite significant progress in modern treatment options, these highly effective therapies are markedly more expensive than conventional replacement therapy, limiting their access for patients in developing countries.

show abstract

“…Pasteurization, terminal dry heat, and vapor heat treatment represent complementary techniques to inactivate lipid-enveloped and selective nonlipid-enveloped pathogens. 21 22 23…”

Section: Plasma-derived Factor VIII Replacement Therapymentioning

confidence: 99%